⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ALLO News
Allogene Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
ALLO
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
globenewswire.com
ALLO
Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update
globenewswire.com
ALLO
Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update
globenewswire.com
ALLO
CAR T-Cell Therapy Market worth $13.78 billion by 2031 | MarketsandMarkets™
prnewswire.com
BMY
GILD
JNJ
CRSP
ALLO
CART
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
globenewswire.com
ALLO
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff
globenewswire.com
ONCY
ALLO
CHRS
PYXS
ELVN
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T
globenewswire.com
ALLO
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis
globenewswire.com
ALLO
CLLS
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
globenewswire.com
ALLO